TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

19 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

14 studies on the map

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis — Northwestern Memorial Hospital, ChicagoEffect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD — Washington DC Veterans Affairs Medical Center (688), Washington D.C.Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis — MGH Institute of Health Professions, BostonMechanism of SGLT2 Inhibition in the Kidney — University of Michigan, Ann ArborHome Based Infusions for Ocrelizumab — Amerita, CentennialProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraStudy of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — Johns Hopkins University, BaltimoreGlucose Consumption in MS Using [F-18]FDG-PET — Brigham & Women's Hospital, BostonSilodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis — Atlantic Health, MorristownOcrelizumab Discontinuation in Relapsing Multiple Sclerosis — Yale School of Medicine, New HavenEmpagliflozin Treatment in Kidney Transplant Recipients — Edward Hines Jr. VA Hospital, Hines, IL, HinesPioglitazone to Reduce Sympathetic Overactivity in CKD Patients — University of Texas at Arlington, ArlingtonOral Iron in Children With Chronic Kidney Disease — Weill Cornell Medicine / New York Presbyterian Hospital, New YorkSafety of Short-course of NSAIDs in Pediatric Patients With CKD — Children's Hospital Colorado, Aurora